Dermatitis News

Upadacitinib showed superior efficacy to dupilumab after 16 weeks of treatment in atopic dermatitis, with higher levels of skin clearance and itch relief, according to a study.

Dupilumab was associated with a rapid onset of action in B and T cells that persisted through a year of therapy in patients with atopic dermatitis, according to a study.

Dupixent reduced both itch and hives in patients with moderate to severe chronic spontaneous urticaria in a pivotal phase 3 trial, Regeneron and Sanofi announced in a press release.

Practitioners should take patient age, available space for the patch and allergy frequency into consideration when determining the best option for pediatric patch testing for allergies, according to a research letter.

Atopic dermatitis symptoms were improved in patients who received selected probiotic strains, according to a study.

Arcutis Biotherapeutics has enrolled the first patient in a phase 3 clinical trial of topical roflumilast foam for the treatment of seborrheic dermatitis, according to a press release.

Adult and adolescent patients with moderate to severe atopic dermatitis had improved symptoms with abrocitinib monotherapy, according to a study of patient-reported outcomes.

A 200 mg single-dose prefilled pen for Dupixent has been approved by the FDA for at-home use to treat certain patients with atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis, according to a company announcement.

Both a 4 mg and 2 mg dosing regimen of oral baricitinib yielded positive outcomes in patients with moderate to severe atopic dermatitis, according to a study.

Pediatric patients with atopic dermatitis who were treated with dupilumab and topical corticosteroids experienced an improvement in both itch and excoriations, according to a study presentation.